Sanofi ends patent dispute with Barr, Teva over allergy drugs
Sanofi-Aventis agreed to resolve patent litigation in the U.S. against Barr Pharmaceuticals and Teva Pharmaceutical Industries over their copies of allergy medicines Nasacort and Allegra. Under the settlement, Sanofi will receive royalty fees in exchange for giving the generic-drug makers nonexclusive licenses to market their versions.
Reuters | 11/19
This story published in FDLI SmartBrief on 11/20/2008
More from SmartBrief:
3 generic-drug makers are sued regarding Angiomax patent
Friday, October 9, 2009
Generics firms oppose higher rebates in Sen. Baucus' health bill
Friday, September 18, 2009
Plan B One-Step contraceptive is approved by FDA
Monday, July 20, 2009
Get stories like these delivered daily for FREE:
|
FDLI SmartBrief
Designed specifically for professionals involved in the food and drug industry, FDLI SmartBrief is a FREE daily e-mail newsletter. It provides the latest need-to-know news and industry information that maximizes your time, giving you an edge over your competition. Learn more |
|